58077-34-2

Basic information

• Product Name: 1,2-Ethanediamine, N-phenyl-N'-(phenylmethyl)-
• CAS NO: 58077-34-2
• Molecular Formula: C15H18N2
• Molecular Weight: 226.321
• Mol File: 58077-34-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1,2-Ethanediamine, N-phenyl-N'-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Ethanediamine, N-phenyl-N'-(phenylmethyl)-(58077-34-2)
• EPA Substance Registry System: 1,2-Ethanediamine, N-phenyl-N'-(phenylmethyl)-(58077-34-2)

Safety Data

• Hazardous Substances Data: 58077-34-2(Hazardous Substances Data)

Usage

Type of compound

Diamine

Functional groups

Two amino groups (-NH2)

Structural features

a. Phenyl group (C6H5) attached to one nitrogen atom
b. Phenylmethyl group (C6H5-CH2) attached to the other nitrogen atom

Common uses

a. Building block in the synthesis of pharmaceuticals
b. Building block in the synthesis of dyes
c. Building block in the synthesis of polymers

Industrial and research applications

Wide range of applications in organic chemistry

Toxicity

Can be toxic if ingested or inhaled

Skin and eye irritation

May cause skin and eye irritation upon contact

Handling and storage

Should be handled and stored with care to avoid exposure and potential health risks

Upstream product

• 64469-51-8 1-benzyl-2,3-diphenyl-imidazolidine 
• 88-89-1 2,4,6-Trinitrophenol 
• 2510-33-0 N-benzyl-2-oxazolidinone 
• 142-04-1 aniline hydrochloride 
• 342406-53-5 N¹-benzyl-N²-phenyloxalamide 
• 13670-23-0 N-(2-(phenylamino)ethyl)benzamide 
• 206753-52-8 4-benzyl-1-phenylpiperazine-2,3-dione 
• 64-17-5 ethanol 
• 861339-06-2 5-chloro-1,2-diphenyl-1H-imidazole 
• 7647-01-0 hydrogenchloride 
• 100-52-7 benzaldehyde 
• 206753-50-6 N-(2-tert-Butoxycarbonylamino-ethyl)-N-phenyl-oxalamic acid methyl ester 
• 206753-73-3 N-[2-(Benzyl-tert-butoxycarbonyl-amino)-ethyl]-N-phenyl-oxalamic acid methyl ester 
• 98-88-4 benzoyl chloride 

Downstream Products

• 135036-19-0 4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide 
• 91532-78-4 4-benzil-3-carbometossi-1-fenilpiperazina 
• 135036-39-4 N-(4-nitrophenyl)-4-phenyl-1-(phenylmethyl)-2-piperazinecarboxamide 
• 135063-15-9 N-(4-nitrophenyl)-1-phenyl-4-(phenylmethyl)-2-piperazinecarboxamide 
• 135036-22-5 1-phenyl-4-(phenylmethyl)-2-piperazinecarbonitrile 

Relevant articles and documents

COMPOUND HAVING γ TURN STRUCTURE AND LSD1 INHIBITOR USING THE SAME

PROBLEM TO BE SOLVED: To provide a compound having LSD1 inhibitory activity and cancer cell growth inhibitory effect. SOLUTION: There is provided a compound represented by the formula (1) and a salt thereof. (1), where R1 is an alkyl group, a cycloalkyl group, an aralkyl group, an aryl group or a heteroaryl group, R2 is H, an alkyl group, a cycloalkyl group, an aryl group or a heteroaryl group, R3 is H, an alkyl group, a cycloalkyl group, an aralkyl group, an aryl group or a heteroaryl group, R4 is an aryl group or a heteroaryl group, each of the above described groups may be substituted, n is an integer of 2 to 10 and *1 and *2 are asymmetric carbons. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPO&INPIT

5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones

Synthetic routes were developed to access a variety of novel 1-aryl- 2H,4H-tetrahydro-1,2,4-triazin-3-one analogs which were evaluated as 5- lipoxygenase (5-LO) inhibitors. The parent structure, 1-phenylperhydro- 1,2,4-triazin-3-one (4), was found to be a

2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use

The present invention provides substituted dibenzoxazepine and dibenzthiazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, and for prostaglandin-E2 mediated diseases, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal, and a method for treating prostaglandin-E2 mediated diseases in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.